Segù Marzia, Campagnoli Giovanna, Di Blasio Marco, Santagostini Antonio, Pollis Matteo, Levrini Luca
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, Section of Dentistry of Pavia, University of Pavia, 27100 Pavia, Italy.
Dent J (Basel). 2022 Jun 6;10(6):99. doi: 10.3390/dj10060099.
This study was conducted to determine the efficacy of a customized mandibular advancement device (MAD) in the treatment of obstructive sleep apnea (OSA). Eight patients (M = 3; F = 5; mean age = 56.3 ± 9.4) with a diagnosis of OSA confirmed by polysomnography (PSG) were recruited on the basis of the following inclusion criteria: apnea-hypopnea index (AHI) > 5, age between 18 and 75 years, body mass index (BMI) < 25, and PSG data available at baseline (T0). All were treated with the new NOA® MAD by OrthoApnea (NOA®) for at least 3 months; PSG with NOA in situ was performed after 3 months of treatment (T1). The following parameters were calculated at T0 and T1: AHI, supine AHI, oxygen desaturation index (ODI), percentage of recording time spent with oxygen saturation <90% (SpO2 < 90%), and mean oxygen desaturation (MeanSpO2%). Data were submitted for statistical analysis. The baseline values were AHI = 21.33 ± 14.79, supine AHI = 35.64 ± 12.80, ODI = 17.51 ± 13.5, SpO2 < 90% = 7.82 ± 17.08, and MeanSpO2% = 93.45 ± 1.86. Four patients had mild OSA (5 > AHI < 15), one moderate OSA (15 > AHI < 30), and three severe OSA (AHI > 30). After treatment with NOA®, statistically significant improvements in AHI (8.6 ± 4.21) and supine AHI (11.21 ± 7.26) were recorded. OrthoApnea NOA® could be an effective alternative in the treatment of OSA: the device improved the PSG parameters assessed.
本研究旨在确定定制下颌前移装置（MAD）治疗阻塞性睡眠呼吸暂停（OSA）的疗效。根据以下纳入标准招募了8例经多导睡眠图（PSG）确诊为OSA的患者（男性3例；女性5例；平均年龄 = 56.3 ± 9.4岁）：呼吸暂停低通气指数（AHI）> 5，年龄在18至75岁之间，体重指数（BMI）< 25，且基线时（T0）有PSG数据。所有患者均使用OrthoApnea公司的新型NOA® MAD治疗至少3个月；治疗3个月后（T1）进行佩戴NOA时的PSG检查。在T0和T1时计算以下参数：AHI、仰卧位AHI、氧饱和度下降指数（ODI）、氧饱和度<90%（SpO2 < 90%）的记录时间百分比以及平均氧饱和度下降（MeanSpO2%）。数据提交进行统计分析。基线值为AHI = 21.33 ± 14.79，仰卧位AHI = 35.64 ± 12.80，ODI = 17.51 ± 13.5，SpO2 < 90% = 7.82 ± 17.08，MeanSpO2% = 93.45 ± 1.86。4例患者为轻度OSA（5 > AHI < 15），1例为中度OSA（15 > AHI < 30），3例为重度OSA（AHI > 30）。使用NOA®治疗后，记录到AHI（8.6 ± 4.21）和仰卧位AHI（11.21 ± 7.26）有统计学意义的改善。OrthoApnea NOA®可能是治疗OSA的一种有效替代方法：该装置改善了所评估的PSG参数。
